drugset / Trial / NCT04444011

Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth

NCT04444011

Phase 1 Unknown 32 enrolled Sihuan Pharmaceutical Holdings Group Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

A single-center, randomized, open-label, crossover study to evaluate the pharmacokinetic drug-drug interaction and safety of the quadruple therapy with Anaprazole 20mg/Amoxicilin 1000mg/Clarithromycin 500mg/Bismuth Potassium Citrate 0.6g in healthy Chinese male subjects.

Timeline

Start
2020-07-01
Primary completion
2020-09-30
Completion
2020-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1000 mg Oral
Subject Anaprazole Other / unclassified 20 mg Oral
Subject Bismuth Potassium Citrate Unknown 0.6 g Oral
Subject Clarithromycin Small molecule 500 mg Oral

Indications

No indication recorded.